Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology (Q38430583)

3 September 2017

1 reference

title

Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology (English)

1 reference

non-small-cell lung carcinoma

3 September 2017

1 reference

1 reference

Sohita Dhillon

1 reference

3 September 2017

publication date

1 June 2015

1 reference

3 September 2017

1 reference

3 September 2017

1 reference

3 September 2017

1 reference

3 September 2017

page(s)

303-310

1 reference

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Second-Line Therapy for Advanced NSCLC

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Novel drugs against non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Bevacizumab: a review of its use in advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Nintedanib for the treatment of patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0367-8

Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25894578

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25894578

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11523-015-0367-8

1 reference

Dimensions Publication ID

3 September 2017

1039020475

0 references

1 reference